The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Other". The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to remember the user consent for the cookies under the category "Analytics". These cookies are set by GDPR Cookie Consent WordPress Plugin. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". The cookie is used to affinitize a client to an instance of an Azure Web App.
#LUPIN MONEYCONTROL WINDOWS#
This cookie is set by websites that run on Windows Azure cloud platform. These cookies ensure basic functionalities and security features of the website, anonymously.
Please consult your investment advisor before investing.Necessary cookies are absolutely essential for the website to function properly. Capital markets investments are subject to rules and regulations. Financial Express Online does not bear any responsibility for their investment advice. (The stock recommendations in this story are by the respective research analysts and brokerage firms. While those at Motilal Oswal Financial Services are neutral on the stock. Axis Securities has recommended to ‘hold’ Lupin shares with a target price of Rs 1,100. It has also revised its rating to ‘reduce’ from ‘add’ earlier.
Those at HDFC Securities Institutional Equities slashed its target price to Rs 1,040 from Rs 1,220 earlier. While Rs 960-883 will be excellent support levels,” AR Ramachandran, Co-founder & Trainer, Tips2Trades, told Financial Express Online.Īnalysts at Emkay Global Financial Services have reiterated their ‘buy’ rating on the stock but cut target price to Rs1,300 from Rs1,325 as it modestly lower its earnings estimates for FY22/23/24 to reflect the Q1 miss, leading to a lower US revenue base.
Long-term investors should start accumulating Lupin at current prices for the near-term targets of Rs 1083-1160. “Technically, the stock is very oversold. Lupin has seen a sharp correction in its stock price due to competition in famotidine & pending USFDA approvals, said an analyst. Rupee likely to depreciate amid persistent FII outflows, widening trade deficit USDINR to trade in this range Therefore, investors can consider holding the stock with a medium to long term perspective,” Chepa added. “We expect its outlook to remain stable on the back of continuous healthy growth in India and gradual ramp-up in US sales which might improve its margins. The operating performance of the firm remained weaker. In traded volume terms, 70,000 shares have traded on BSE, and 15.28 lakh shares exchanged hands on NSE. Since then, this pharma stock has tanked over 24 per cent. Lupin stock surged to a new 52-week high of Rs 1,267.50 apiece in February this year. Check live prices: Lupinīig Bull Rakesh Jhunjhunwala holds 1.60 per cent stake or 72.45 lakh shares in Lupin as of June quarter. “Although the company’s Q1 performance was disappointing, its broader narrative on growth remains largely on track,” Likhita Chepa, Senior Analyst at CapitalVia Global Research told Financial Express Online. Lupin has witnessed a significant amount of correction in the last few trading sessions after the firm failed to meet the earnings expectations of the analysts. Lupin shares have tumbled nearly 17 per cent in seven sessions, falling from Rs 1,150.90 on 6 August 2021. Lupin share price fell nearly 2 per cent to Rs 958.70 apiece in intraday deals, following the April-June quarter earnings last week.
0 kommentar(er)
